drugset
drugset / Trial / NCT03890809

An Investigational Study of BMS-986165 in Participants With Normal Liver Function and Participants With Mild to Severe Liver Damage

NCT03890809 ↗

Phase 1 Completed 32 enrolled Bristol-Myers Squibb
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate BMS-986165 in participants with different levels of liver function.

Timeline

Start
2019-02-26
Primary completion
2019-11-30
Completion
2019-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject CRAVACITINIB Small molecule — Oral

Indications

liver disorder